Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Fenwick, Peter S ^a   Macedo, Patricia ^a   Kilty, Iain C ^b   Barnes, Peter J ^a   Donnelly, Louise E ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 (1H BENZ[D]IMIDAZOL 2 YL) 1H INDAZOL 6 YL] 3 ETHYLPHENOL; ANTIINFLAMMATORY AGENT; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DEXAMETHASONE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE INHIBITOR; MESSENGER RNA; PF 956980; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHEMOKINE RECEPTOR CXCR3; PROTEIN KINASE INHIBITOR;

AGED; ARTICLE; CELL VIABILITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CXCL10 GENE; CXCL11 GENE; CXCL9 GENE; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; MALE; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION; SMOKING; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MIDDLE AGED; RESPIRATORY MUCOSA; SECRETION (PROCESS);

AGED; CELL LINE; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINE CXCL9; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INHIBITORY CONCENTRATION 50; JANUS KINASES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTORS, CXCR3; RESPIRATORY MUCOSA; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 84939162409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128757     Document Type: Article

References (40)

1. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011; 378(9795): 1015-26. doi: 10.1016/S0140-6736(11)60988-4 PMID: 21907865
2. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, Baraldo S, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 165(10): 1404-9. Epub 2002/05/23. PMID: 12016104.
3. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160(2): 711-7. Epub 1999/08/03. PMID: 10430750.
4. Chrysofakis G, Tzanakis N, Kyriakoy D, Tsoumakidou M, Tsiligianni I, Klimathianaki M, et al. Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest. 2004; 125(1): 71-6. Epub 2004/01/14. PMID: 14718423.
5. Siena L, Gjomarkaj M, Elliot J, Pace E, Bruno A, Baraldo S, et al. Reduced apoptosis of CD8+ T-lymphocytes in the airways of smokers with mild/moderate COPD. Respir Med. 2011; 105(10): 1491-500. Epub 2011/05/27. doi: 10.1016/j.rmed.2011.04.014 PMID: 21612902.
6. Mannino DM, Buist AS. Global burden of COPD: Risk factors, prevalence, and future trends. Lancet. 2007; 370(9589): 765-73. Epub 2007/09/04. doi: 10.1016/S0140-6736(07)61380-4 PMID: 17765526.
7. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet. 2007; 370 (9589): 741-50. Epub 2007/09/04. doi: 10.1016/S0140-6736(07)61377-4 PMID: 17765523.
8. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009; 373 (9678): 1905-17. Epub 2009/06/02. doi: 10.1016/S0140-6736(09)60326-3 PMID: 19482216.
9. Groom JR, Luster AD. CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011; 89(2): 207-15. Epub 2011/01/12. doi: 10.1038/icb.2010.158 PMID: 21221121.
10. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, et al. Chemokine receptor specific for IP10 and MIG: Structure, function, and expression in activated T-lymphocytes. J Exp Med. 1996; 184(3): 963-9. Epub 1996/09/01. PMID: 9064356; PubMed Central PMCID: PMC2192763.
11. Costa C, Rufino R, Traves SL, Lapa ESJR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest. 2008; 133(1): 26-33. Epub 2007/10/11. doi: 10.1378/chest.07-0393 PMID: 17925429.
12. Warwick G, Thomas PS, Yates DH. Non-invasive biomarkers in exacerbations of obstructive lung disease. Respirology. 2013; 18(5): 874-84. Epub 2013/03/26. doi: 10.1111/resp.12089 PMID: 23521049.
13. Quint JK, Donaldson GC, Goldring JJ, Baghai-Ravary R, Hurst JR, Wedzicha JA. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest. 2010; 137(4): 812-22. Epub 2009/10/20. doi: 10.1378/chest.09-1541 PMID: 19837822; PubMed Central PMCID: PMCPmc2851557.
14. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, et al. The T cell-specific CXC chemokines IP-10, MIG, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol. 1999; 162(6): 3549-58. PMID: 10092813
15. Tudhope SJ, Catley MC, Fenwick PS, Russell RE, Rumsey WL, Newton R, et al. The role of I?B kinase 2, but not activation of NF-?B, in the release of CXCR3 ligands from IFN-?-stimulated human bronchial epithelial cells. J Immunol. 2007; 179(9): 6237-45. PMID: 17947699
16. Pechkovsky DV, Goldmann T, Ludwig C, Prasse A, Vollmer E, Muller-Quernheim J, et al. CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. Respiratory Research. 2005; 6(1): 75. Epub 2005/07/22. doi: 10.1186/1465-9921-6-75 PMID: 16033640; PubMed Central PMCID: PMC1185567.
17. Hardaker EL, Bacon AM, Carlson K, Roshak AK, Foley JJ, Schmidt DB, et al. Regulation of TNF-alphaand IFN-gamma-induced CXCL10 expression: Participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease. FASEB J. 2004; 18(1): 191-3. Epub 2003/11/05. doi: 10.1096/fj.03-0170fje PMID: 14597565.
18. Murray PJ. The JAK-STAT signaling pathway: Input and output integration. J Immunol. 2007; 178 (5): 2623-9. Epub 2007/02/22. PMID: 17312100.
19. Meinke A, Barahmand-Pour F, Wohrl S, Stoiber D, Decker T. Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol. 1996; 16(12): 6937-44. Epub 1996/12/01. PMID: 8943349; PubMed Central PMCID: PMC231697.
20. Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFN? signaling-Does it mean JAK-STAT? Cytokine Growth Factor Reviews. 2008; 19(5): 383-94. doi: 10.1016/j.cytogfr.2008.08.004 PMID: 18929502
21. Clarke DL, Clifford RL, Jindarat S, Proud D, Pang L, Belvisi M, et al. TNFa and IFN? Synergistically Enhance Transcriptional Activation of CXCL10 in Human Airway Smooth Muscle Cells via STAT-1, NF-?B, and the Transcriptional Coactivator CREB-binding Protein. J Biol Chem. 2010; 285(38): 29101-10. doi: 10.1074/jbc.M109.0999952 PMID: 20833730
22. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factoralpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996; 153(2): 530-4. Epub 1996/02/01. PMID: 8564092.
23. Cox MA, Jenh CH, GonsiorekW, Fine J, Narula SK, Zavodny PJ, et al. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: Differential binding to receptor states. MolPharmacol. 2001; 59(4): 707-15. PMID: 11259614
24. Changelian PS, Moshinsky D, Kuhn CF, Flanagan ME, Munchhof MJ, Harris TM, et al. The specificity of JAK3 kinase inhibitors. Blood. 2008; 111(4): 2155-7. Epub 2007/12/21. doi: 10.1182/blood-2007-09-115030 PMID: 18094329.
25. Coe JWD, D.M.; Jones, P.; Kortum, S.W.; Sabnis, Y.A.; Wakenhut, F.M.; Whitlock, G.A., inventorIndazoles2013 2013.
26. ATS. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med. 1995; 152(5 Pt 2): S77-121. PMID: 7582322
27. Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, et al. Validation of the anti-inflammatory properties of small molecule I kappa B kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol. 2006; 70(2): 697-705. doi: 10.1124/mol.106.023150 PMID: ISI: 000239117900030.
28. Wang Z, Zheng T, Zhu Z, Homer RJ, Riese RJ, Chapman HA Jr., et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000; 192(11): 1587-600. Epub 2000/12/06. PMID: 11104801; PubMed Central PMCID: PMC2193095.
29. Saetta M, Di Stefano A, Maestrelli P, Ferraresso A, Drigo R, Potena A, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993; 147(2): 301-6. Epub 1993/02/01. PMID: 8430952.
30. Freeman CM, Curtis JL, Chensue SW. CC Chemokine Receptor 5 and CXC Chemokine Receptor 6 Expression by Lung CD8+ Cells Correlates with Chronic Obstructive Pulmonary Disease Severity. Am J Pathol. 2007; 171(3): 767-76. PMID: 17640964
31. Culpitt SV, Rogers DF, Traves SL, Barnes PJ, Donnelly LE. Sputum matrix metalloproteases: Comparison between chronic obstructive pulmonary disease and asthma. Respir Med. 2005; 99(6): 703-10. PMID: 15878486
32. Burnett D, Chamba A, Hill SL, Stockley RA. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet. 1987; 2(8567): 1043-6. PMID: 2889963
33. Van den Steen PE, Husson SJ, Proost P, Van Damme J, Opdenakker G. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun. 2003; 310(3): 889-96. Epub 2003/10/11. PMID: 14550288.
34. Steele AJ, Prentice AG, Cwynarski K, Hoffbrand AV, Hart SM, Lowdell MW, et al. The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: Potential for reversal of cytoprotection by the microenvironment. Blood. 2010; 116(22): 4569-77. Epub 2010/08/19. doi: 10.1182/blood-2009-09-245811 PMID: 20716767.
35. Hu X, Ivashkiv LB. Cross-regulation of Signaling Pathways by Interferon-?: Implications for Immune Responses and Autoimmune Diseases. Immunity. 2009; 31(4): 539-50. doi: 10.1016/j.immuni.2009.09. 002 PMID: 19833085
36. Yang CH, Wei L, Pfeffer SR, Du Z, Murti A, Valentine WJ, et al. Identification of CXCL11 as a STAT3-Dependent Gene Induced by IFN. J Immunol. 2007; 178(2): 986-92. PMID: 17202361
37. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Ann N Y Acad Sci. 2009; 1171(1): 59-76. Epub 2009/09/03. doi: 10.1111/j.1749-6632.2009.04911.x PMID: 19723038; PubMed Central PMCID: PMC3141289.
38. Ke Y, Reddel RR, Gerwin BI, Miyashita M, McMenamin M, Lechner JF, et al. Human bronchial epithelial cells with integrated SV40 virus T antigen genes retain the ability to undergo squamous differentiation. Differentiation. 1988; 38(1): 60-6. Epub 1988/06/01. PMID: 2846394.
39. Hsu L, Armstrong AW. JAK inhibitors: Treatment efficacy and safety profile in patients with psoriasis. Journal of immunology research. 2014; 2014: 283617. Epub 2014/06/03. doi: 10.1155/2014/283617 PMID: 24883332; PubMed Central PMCID: PMC4027021.
40. Vyas D, O'Dell KM, Bandy JL, Boyce EG. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2013; 47(11): 1524-31. Epub 2013/11/29. doi: 10. 1177/1060028013512790 PMID: 24285764.